Chimerix's Drug Candidate Improves Survival for Patients with Incurable Brain Tumor

The company’s first-in-class small molecule imipridone, ONC201, showed strong efficacy results in two early-stage clinical trials of 71 pediatric patients with H3K27M-mutant diffuse midline gliomas.

Related Keywords

Michigan ,United States ,Mike Andriole ,Carl Koschmann ,Sriram Venneti , ,Chimerixannounced Wednesday ,Cancer Discovery ,Chad Carr Pediatric Brain Tumor Center ,Michigan Medicine ,Resume ,Careers ,Himerixs Drug Candidate Improves Survival For Patients With Incurable Brain Tumor ,Iospace ,Advice ,